An observational study in Cardiovascular Morbidity, Cardiovascular Risk Assesment and Primary Prevention CVD, sponsored by National Institute of Cardiovascular Diseases, Pakistan. Recruiting at 1 site in Pakistan. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by National Institute of Cardiovascular Diseases, Pakistan · Observational
More research is needed to articulate the most effective ways to use these tools as screening tests in cardiovascular risk assessments and how they ultimately affect CVD mortality and morbidity outcomes. Clinicians are encouraged to continue sharing decision-making with patients to combine their unique cardiovascular risk factors and develop a comprehensive, effective treatment plan.
Study Design: observational study Duration of Study: ongoing. Sample Size: All patients presenting to preventive cardiology clinics at the National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan..
Sampling Technique: Non-probability consecutive sampling Data Collection Procedure: Verbal informed consent will be obtained from all the patients regarding their participation in the study and publication of study findings while maintaining confidentiality. Consecutive patients presenting preventive cardiology clinics at the National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan, will be included in this registry. Demographic characteristics, physical examination, clinical history, risk modification, lab assessment, and ASCVD risk score at presentation and at every follow-up will be recorded using a structural questionnaire.
Data Analysis Procedure: The Tentative analysis plan uses collected data for research publications. The statistical package for social sciences (SPSS 21) will be used to analyze baseline characteristics. The Shapiro-Wilk test will be applied to check the hypothesis of normality for quantitative (continuous) variables. Descriptive statistics such as mean ± SD, median (IQR), skewness, maximum, and minimum will be calculated for quantitative (continuous) variables. Frequency and percentages will be calculated for categorical variables.
Both genders, age 18 and above, visiting preventive cardiology clinics with or without established CVD and may or may not have CVD risk factors.
Exclusion Criteria:
Adult patients with or without cardiovascular diseases.
Other: Cardiovascular risk assesment
ASCVD Score and WHO Cardiovascular Risk score.
cardiovascular risk assesesment
risk stratification of Cardiovascular diseases (CVD) in patients without established CVD but with CVD co morbids.we are using Atherosclerotic Cardiovascular Diseases (ASCVD) Risk Score and World Heart Organization(WHO) Risk Score for CVD Risk Assesment. In ASCVD Risk Score, we categorize population into low risk ( score \<5), borderline(score between 5 and 7.4) ,intermediate( score between 7.5 an 19.9) and high risk (score\>20), using all parameters for risk assesment. For WHO risk score calculation we are using WHO Risk score system for South Asia. https://cdn.who.int/media/docs/default-source/cardiovascular-diseases/south-asia.pdf?sfvrsn=c5b0d9a3\_2
Time frame: Ten years
Cardiovascular risk reduction
CVD risk reduction in patients with or without established CVD but with CVD co morbids.
Time frame: Ten years
Cardiovascular related deaths
Estimation of patients who expired in their follow up despite CVD risk factors management.
Time frame: Ten years.
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Institute of Cardiovascular Diseases, Pakistan